REQUITE

Validating predictive models of radiotherapy toxicity to improve quality-of-life and reduce side-effects in cancer survivors

 Coordinatore THE UNIVERSITY OF MANCHESTER 

 Organization address address: OXFORD ROAD
city: MANCHESTER
postcode: M13 9PL

contact info
Titolo: Ms.
Nome: Claire
Cognome: Faichnie
Email: send email
Telefono: 441613000000

 Nazionalità Coordinatore United Kingdom [UK]
 Sito del progetto http://www.requite.eu/
 Totale costo 7˙821˙718 €
 EC contributo 5˙997˙408 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2013-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-10-01   -   2018-09-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    THE UNIVERSITY OF MANCHESTER

 Organization address address: OXFORD ROAD
city: MANCHESTER
postcode: M13 9PL

contact info
Titolo: Ms.
Nome: Claire
Cognome: Faichnie
Email: send email
Telefono: 441613000000

UK (MANCHESTER) coordinator 959˙167.00
2    UNIVERSITY OF LEICESTER

 Organization address address: University Road
city: LEICESTER
postcode: LE1 7RH

contact info
Titolo: Mrs.
Nome: Marie
Cognome: Adams
Email: send email
Telefono: +44 116 252 2783
Fax: +44 116 252 2028

UK (LEICESTER) participant 894˙431.00
3    DEUTSCHES KREBSFORSCHUNGSZENTRUM

 Organization address address: Im Neuenheimer Feld 280
city: HEIDELBERG
postcode: 69120

contact info
Titolo: Dr.
Nome: Ina
Cognome: Wiest
Email: send email
Telefono: +49 6221 2700
Fax: +49 6221 2708

DE (HEIDELBERG) participant 747˙783.00
4    Source Bioscience plc

 Organization address address: "ORCHARD PLACE, BUSINESS PARK 1"
city: NOTTINGHAM
postcode: NG8 6PX

contact info
Titolo: Mr.
Nome: Nick
Cognome: Cox
Email: send email
Telefono: 441160000000

UK (NOTTINGHAM) participant 724˙000.00
5    KATHOLIEKE UNIVERSITEIT LEUVEN

 Organization address address: Oude Markt 13
city: LEUVEN
postcode: 3000

contact info
Titolo: Dr.
Nome: Myriam
Cognome: Witvrouw
Email: send email
Telefono: 3216320623
Fax: 3216326515

BE (LEUVEN) participant 637˙928.00
6    UNIVERSITEIT GENT

 Organization address address: SINT PIETERSNIEUWSTRAAT 25
city: GENT
postcode: 9000

contact info
Titolo: Ms.
Nome: Nathalie
Cognome: Vandepitte
Email: send email
Telefono: 3292643029

BE (GENT) participant 483˙985.00
7    INSTITUT REGIONAL DU CANCER DE MONTPELLIER

 Organization address address: RUE DE LA CROIX VERTE 31 PARC EUROMEDECINE
city: MONTPELLIER
postcode: 34090

contact info
Titolo: Mrs.
Nome: Nathalie
Cognome: Coux
Email: send email
Telefono: 33467613102

FR (MONTPELLIER) participant 425˙448.00
8    STICHTING MAASTRICHT RADIATION ONCOLOGY MAASTRO CLINIC

 Organization address address: Dr. Tanslaan 12
city: Maastricht
postcode: 6229 ET

contact info
Titolo: Ms.
Nome: Floor
Cognome: Franssen
Email: send email
Telefono: +31 088 44 55 605
Fax: +31 088 44 55 776

NL (Maastricht) participant 237˙800.00
9    FUNDACION PUBLICA GALEGA DE MEDICINA XENOMICA

 Organization address city: Santiago de Compostela
postcode: 15706

contact info
Titolo: Ms.
Nome: Ana
Cognome: Ezara Trillo
Email: send email
Telefono: +34 981951491
Fax: +34 981951473

ES (Santiago de Compostela) participant 237˙280.00
10    THE CHRISTIE NHS FOUNDATION TRUST

 Organization address address: WILMSLOW ROAD 1
city: MANCHESTER
postcode: M20 4BX

contact info
Titolo: Ms.
Nome: Sally
Cognome: Smillie
Email: send email
Telefono: +44 161 9187493

UK (MANCHESTER) participant 189˙652.00
11    FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI

 Organization address address: Via Venezian 1
city: Milan
postcode: 20133

contact info
Titolo: Dr.
Nome: Antonio
Cognome: Cannarozzo
Email: send email
Telefono: +39 02 2390 3419
Fax: +39 02 2390 3132

IT (Milan) participant 177˙088.00
12    RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG

 Organization address address: SEMINARSTRASSE 2
city: HEIDELBERG
postcode: 69117

contact info
Titolo: Mrs.
Nome: Anke
Cognome: Keller
Email: send email
Telefono: +49 621 383 4493

DE (HEIDELBERG) participant 123˙840.00
13    ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

 Organization address address: ONE GUSTAVE L LEVY PLACE BOX 1075
city: NEW YORK
postcode: 10029 6574

contact info
Titolo: Prof.
Nome: Barry
Cognome: Rosenstein
Email: send email
Telefono: +1212 241 9408

US (NEW YORK) participant 84˙014.00
14    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

 Organization address address: The Old Schools, Trinity Lane
city: CAMBRIDGE
postcode: CB2 1TN

contact info
Titolo: Ms.
Nome: Renata
Cognome: Schaeffer
Email: send email
Telefono: +44 1223 333543
Fax: +44 1223 332988

UK (CAMBRIDGE) participant 66˙592.00
15    UNIVERSITE DE MONTPELLIER

 Organization address address: 163 RUE AUGUSTE BROUSSONNET
city: MONTPELLIER
postcode: 34090

contact info
Titolo: Mrs.
Nome: Vanessa
Cognome: Guillaumon
Email: send email
Telefono: +33 4 67 61 31 61

FR (MONTPELLIER) participant 8˙400.00
16    UNIVERSITE MONTPELLIER I

 Organization address address: BOULEVARD HENRI IV 5
city: MONTPELLIER
postcode: 34967

contact info
Titolo: Mrs.
Nome: Vanessa
Cognome: Guillaumon
Email: send email
Telefono: +33 4 67 61 31 61

FR (MONTPELLIER) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

incorporate    biomarker    predictive    million    patients    clinical    survivors    biomarkers    interventional    data    trial    qol    reducing    cancer    models    validate    validated    risk    radiotherapy    published    protocols    requite   

 Obiettivo del progetto (Objective)

'Long-term side-effects of radiotherapy impact on the quality-of-life (QoL) of cancer survivors. These side-effects could be reduced if predicted in advance. Previous work identified clinical and biological predictors but a major, coordinated approach is needed to validate them so they can be used clinically. The EU has ~17.8 million people living with a prior diagnosis of cancer of whom ~7 million received radiotherapy. In the long-term, potentially 20% of those suffering with mild to severe side-effects (~1.4 million) might benefit from alleviation of symptoms, with resulting reductions in the cost of care in the EU. REQUITE aims to develop validated clinical models and incorporate biomarkers to identify before treatment cancer patients at risk of side-effects and use the models to design interventional trials aimed at reducing side-effects and improving QoL in cancer survivors who underwent radiotherapy. REQUITE will: 1. carry out a multi-centre, longitudinal, observational study to collect standardised data and samples in breast, prostate and lung cancer patients; 2. validate biomarkers with published evidence of predictive value; 3. replicate published clinical models and incorporate replicated biomarkers to create validated predictive algorithms; 4. use the prospectively validated models and biomarkers to design interventional trial protocols aiming to reduce side-effects and improve QoL in high-risk patients. REQUITE builds on collaborations with a proven history of data sharing, enlarged to a consortium with expertise in patient recruitment, knowledge management, biomarker testing and predictive model development. SME involvement for biomarker assays will facilitate future clinical implementation and commercial exploitation. The outcome of this project will be validated predictive models for three common cancers and trial protocols using the models to investigate interventions aimed at reducing long-term side-effects and improving the QoL of cancer survivors.'

Altri progetti dello stesso programma (FP7-HEALTH)

ONCOMIRS (2008)

MicroRNAs and Cancer: From Bench to Bedside

Read More  

READNA (2008)

REvolutionary Approaches and Devices for Nucleic Acid Analysis

Read More  

HEALTH-NCP-NET (2008)

Coordination Action for Reinforcing the Health National Contact Points Network

Read More